YKYeong Hoon Kim

Yeong Hoon Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yeong Hoon Kim has a total of 289 co-authors. Here are the top co-authors by number of shared publications:

  • Kook-Hwan Oh

    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Kidney Research Institute, Seoul National University Medical Research Center, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

    13 shared publications
  • Curie Ahn

    Division of Nephrology, National Medical Center, Seoul, South Korea

    10 shared publications
  • Soo Wan Kim

    Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea

    10 shared publications
  • Yun Kyu Oh

    Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea

    10 shared publications
  • Seung Hyeok Han

    Department of Internal Medicine and Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea

    9 shared publications
  • Sun Woo Kang

    Department of Internal Medicine Inje University Busan Paik Hospital Busan South Korea

    8 shared publications

Latest Publications

  • Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in Chronic Kidney Disease

    by Minsang Kim, Sanyeowool An, Hyunjin Ryu, Choonghyun Sun, Hong Yul An, Gangpyo Ryu, Jayoun Kim, Yaeni Kim, Soo Wan Kim, Yeong Hoon Kim, et al.

    Background: Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with inflammation. Although chronic kidney disease (CKD) shares these pathophysiological features, the prognostic role of CHIP on CKD progression remains unclear, particularly in underrepresented East Asian populations. Methods: Deep-targeted sequencing of CHIP-driving mutations was used to identify the presence of CHIP, defined as variant allele fraction (VAF) ≥2.0%. CHIP prevalence was compared between 175 Korean patients with CKD in the KNOW-CKD cohort and 700 matched general population controls in the GENIE cohort. The association between CHIP and kidney failure (KF) risk was evaluated using multivariable Cox regression analysis both in the KNOW-CKD cohort and 232 matched UK Biobank participants with CKD. Furthermore, VAF was compared between CHIP-positive participants in the KNOW-CKD and GENIE cohorts. Results: The prevalence of CHIP was significantly higher in the KNOW-CKD than in the GENIE cohort (17% vs. 11%; P = 0.04). Over a median follow-up of 10.0 years, 66 patients (38%) developed KF in the KNOW-CKD cohort. After multivariable adjustment, CHIP was associated with higher risk of KF (adjusted hazard ratio [aHR], 1.90; 95% CI, 1.03–3.51). Furthermore, in the UK Biobank, KF occurred in 43 participants (20%) over a median follow-up of 12.9 years and the association of CHIP with higher risk of KF was consistently observed (aHR, 2.16; 95% CI, 1.15–4.03). Furthermore, among CHIP-positive participants, the median VAF of CHIP-associated mutations was significantly higher in persons within the KNOW-CKD cohort compared to healthy controls in the GENIE cohort (7.3% vs. 4.4%; P = 0.02). Conclusions: CHIP is more prevalent in patients with CKD and serves as an independent risk factor for KF. This association is consistently observed across both an underrepresented East Asian cohort and a European cohort, establishing CHIP as a globally relevant risk factor for CKD progression.

  • Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equation for Adverse Cardio-Kidney Outcomes in Chronic Kidney Disease Population

    by Byounghwi Ko, Chan-Young Jung, Ye Eun Ko, Hee Byung Koh, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Seung Hyeok Han, Shin-Wook Kang, Jayoun Kim, et al.

    Background: Chronic kidney disease (CKD) substantially increases cardiovascular disease (CVD) and mortality risks, yet few models account for integrated cardio-kidney outcomes (CKOs). The American Heart Association’s PREVENT (Predicting Risk of CVD Events) score incorporates kidney-specific measures, however, its accuracy for CKOs in patients with CKD remains unclear. We aimed to evaluate PREVENT for CKOs against the Pooled Cohort Equation (PCE) and Systematic Coronary Risk Evaluation 2 (SCORE2) in two ethnically distinct CKD cohorts: KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease [KNOW-CKD] from South Korea and Chronic Renal Insufficiency Cohort [CRIC] from the United States. Methods: This study included 4,268 patients with CKD and no known CVD (CRIC: 2,530, KNOW-CKD: 1,738). We compared PREVENT (CVD and ASCVD versions) with the PCE and SCORE2. The primary outcome was CKO, a composite of major adverse kidney events (MAKE: ≥50% estimated glomerular filtration rate decline or kidney failure requiring replacement therapy) and four-point-major adverse cardiovascular events (4P-MACE). Secondary outcomes included individual components and all-cause mortality. Results: The PREVENT-CVD score showed superior predictive accuracy for CKO (Harrell’s C: 0.688; 95% confidence interval [CI]: 0.675–0.701) compared with PREVENT-ASCVD (ΔC = –0.009; 95% CI: –0.011 to –0.007), PCE (ΔC = –0.104; 95% CI: –0.113 to –0.095), and SCORE2 (ΔC = –0.106; 95% CI: –0.114 to –0.097). This superiority was driven by robust prediction for MAKE, along with significant improvements in reclassification and discrimination for 4P-MACE and all-cause mortality. Although predictive gains for 4P-MACE were attenuated in the KNOW-CKD cohort, adding albuminuria further enhanced predictive performance for primary outcome. Conclusions: The PREVENT-CVD equation outperformed traditional cardiovascular risk models in predicting integrated CKOs in patients with CKD. Its consistent discrimination across both cardiovascular and kidney events suggests that PREVENT may reflect the shared pathophysiology of cardio-kidney disease and support broader risk stratification in CKD.


  • Open Access

    Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report

    by Hayne Cho Park, Yong Chul Kim, Hyunsuk Kim, Yaerim Kim, Hyun Jin Ryu, Yong Soo Kim, Wookyung Chung, Yong-Lim Kim, Seungyeup Han, Yeonsoon Jung, et al.

    Background: Tolvaptan, a selective vasopressin V2 receptor antagonist, was first approved by the Korean Ministry of Food and Drug Safety in 2015 as a treatment option for autosomal dominant polycystic kidney disease (ADPKD). To prescribe tolvaptan safely and effectively, we designed the phase 4 clinical trial among Korean ADPKD patients with chronic kidney disease stages 1 to 3.Methods: A total of 117 Korean patients aged 19 to 50 years with rapidly progressing ADPKD were enrolled in the study. Tolvaptan was prescribed for 24 months with the maximum tolerable dose up to 120 mg/day. The primary outcome was the incidence of treatment-emergent adverse events (TEAEs) including hepatic adverse events. The secondary outcomes were the annual mean percent change of total kidney volume (TKV) and the annual mean change of estimated glomerular filtration rate (eGFR).Results: A total of 489 TEAEs occurred in 106 patients (90.6%). A total of 17 cases of hepatic adverse events (14.5%) occurred during the study period and mostly within the first 18-month period. However, liver enzymes were normalized after drug discontinuation. Although it was not statistically significant, patients with a previous history of liver disease as well as those with mild elevation of liver enzyme showed a higher frequency of hepatic adverse events. Compared with the predicted value from the calculation, tolvaptan attenuated both TKV growth and eGFR decline rate.Conclusion: Although the incidence of hepatic adverse events was higher in Korean ADPKD patients compared to the previous studies, tolvaptan can be prescribed safely and effectively using meticulous titration and 1-month interval monitoring.


  • Open Access

    Genetically predicted vitamin D and risk of chronic kidney disease progression: a Mendelian randomization study

    by Juyeon Lee, Sangjun Lee, Sungji Moon, Yaeni Kim, Soo Wan Kim, Yeong Hoon Kim, Miyeon Han, Kook-Hwan Oh, Sue K. Park

    Background: Chronic kidney disease (CKD) is a global health burden, with vitamin D deficiency being a prevalent and modifiable risk factor. Vitamin D is involved in calcium-phosphate homeostasis, immune regulation, and anti-inflammatory pathways. However, its causal role in CKD progression remains uncertain. Methods: This study employed Mendelian randomization (MR) using genome-wide association study data to assess the causal effects of genetically predicted 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] levels on CKD progression in a KNOW-CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) cohort. CKD progression was defined as the estimated glomerular filtration rate (eGFR) slope, calculated using a linear mixed model to represent the rate of kidney function decline. Six MR methods were applied to ensure robust causal inference. Results: Genetic variants associated with higher 25(OH)D levels were linked to a significantly slower decline in eGFR, suggesting a protective effect on kidney function. Inverse variance weighted (IVW) analysis showed a negative association between genetically predicted 25(OH)D levels and eGFR slope (β =-0.246, SE = 0.093, p = 8.54E-03). A similar association was observed for 1,25(OH) 2 D using the radial IVW method (β =-0.256, SE = 0.057, p = 8.84E-06), with consistent findings from IVW and weighted median methods (p = 5.50E-04 and p = 1.13E-02, respectively). Sensitivity analyses using MR-Egger and MR-PRESSO showed no evidence of directional pleiotropy. Conclusion: This study provides evidence for a protective role of vitamin D in CKD progression, emphasizing the importance of maintaining adequate vitamin D levels. These findings highlight the potential for vitamin D-targeted therapeutic strategies in CKD management.

  • Open Access

    Impact of Tacrolimus Trough Levels at Discharge on Early Post-Kidney Transplantation Outcomes: A Nationwide Cohort Study

    by Heungman Jun, Young Ju Oh, Hyo Kee Kim, Jun Young Lee, Yeong Hoon Kim, Joong Kyung Kim, Jaeseok Yang, Myoung Soo Kim, Cheol Woong Jung, Korean Organ Transplantation Registry Study Group

    Introduction: Tacrolimus is a cornerstone immunosuppressant in kidney transplantation (KT), but its narrow therapeutic index necessitates precise monitoring. Early post-transplant tacrolimus trough concentrations (C0) are critical, as suboptimal levels can increase rejection and infection risks. This study evaluated the impact of C0 levels at discharge on early post-transplant outcomes in a large Korean cohort. Materials and Methods: This retrospective analysis included 5293 KT recipients from the Korean Organ Transplant Registry (KOTRY) who received a kidney transplant between 2014 and 2019. Recipients were categorized into three groups based on C0 levels at discharge: 9.5 ng/mL. Clinical outcomes, including serum creatinine (sCr), biopsy-proven acute rejection (BPAR), and infections requiring hospitalization, were analyzed using the Kruskal–Wallis test and chi-squared test. Results: The BPAR rates were 22.5%, 20.9%, and 21.5% for the low, middle, and high C0 groups, respectively (p = 0.221). However, the incidence of infections requiring hospitalization was significantly higher in the high C0 group (28.1%) compared to the middle (23.9%) and low (21.7%) groups at 1-year follow-up (p < 0.001). In high-risk recipients, lower C0 levels correlated with increased BPAR rates (33.9% vs. 29.1% and 26.4%, p = 0.030). Higher intrapatient variability (IPV) between discharge and 6 months was linked to higher infection risk in all recipients and increased BPAR and infection risk in high-risk patients. Conclusions: Optimal C0 levels at discharge are essential to balance rejection and infection risks in KT. Lower C0 levels and higher IPV increase the risk of adverse outcomes, especially in high-risk sensitized recipients, underscoring the need for careful monitoring and personalized management.

  • Open Access

    Clinical significance of the living kidney donor profile index for predicting long-term posttransplant outcomes: results from the Korean Organ Transplantation Registry

    by Jong Ho Kim, Sang Ho Lee, Jin Sug Kim, Hyeon Seok Hwang, Hyunmin Ko, Cheol-Woong Jung, Deok Gie Kim, Yeong Hoon Kim, Jaeseok Yang, Curie Ahn, et al.

    Background: The usefulness of the living kidney donor profile index (LKDPI) has not been widely demonstrated; therefore, it requires verification before clinical application. We analyzed the LKDPI using data from the Korean Organ Transplantation Registry (KOTRY) to confirm whether the LKDPI can be used to predict the survival of allografts in living donor kidney transplantation (LDKT) patients in Korea. Methods: The study population was obtained from the KOTRY database. A total of 2,598 kidney recipients registered in the KOTRY database were enrolled between May 2014 and December 2020. Donor and recipient information was observed, and the LKDPI was measured. Results: Median LKDPI score was 15.5 with a follow-up duration of 33.7 ± 16.1 months. According to LKDPI scores (group 1, 40), LKDPI group 4 had significantly higher death-censored graft loss than LKDPI group 1 (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.06– 3.40; p = 0.03). When divided based on the cutoff value (LKDPI, 36.6), the high LKDPI group had higher graft loss than the low LKDPI group (HR, 2.14; 95% CI, 1.37–3.34; p < 0.001). When follow-up was repeated after transplantation, it was confirmed that the higher the LKDPI value was, the lower the average estimated glomerular filtration rate (p < 0.001). Conclusion: This study confirmed that LKDPI can serve as an independent predictor for assessing the risk of allograft failure and transplant outcomes in Korean LDKT patients.

  • Open Access

    Efficacy of Integrated Risk Score Using Omics-Based Biomarkers for the Prediction of Acute Rejection in Kidney Transplantation: A Randomized Prospective Pilot Study

    by Jeong-Hoon Lim, Byung Ha Chung, Sang-Ho Lee, Jong Soo Lee, Yeong Hoon Kim, Man-Hoon Han, Hee-Yeon Jung, Ji-Young Choi, Jang-Hee Cho, Sun-Hee Park, et al.

    Acute rejection (AR) is critical for long-term graft survival in kidney transplant recipients (KTRs). This study aimed to evaluate the efficacy of the integrated risk score of omics-based biomarkers in predicting AR in KTRs. This prospective, randomized, controlled, multicenter, pilot study enrolled 40 patients who recently underwent high-immunologic-risk kidney transplantation (KT). Five omics biomarkers were measured, namely, blood mRNA (three-gene signature), urinary exosomal miRNA (three-gene signature), urinary mRNA (six-gene signature), and two urinary exosomal proteins (hemopexin and tetraspanin-1) at 2 weeks and every 4 weeks after KT for 1 year. An integrated risk score was generated by summing each biomarker up. The biomarker group was informed about the integrated risk scores and used to adjust immunosuppression, but not the control group. The outcomes were graft function and frequency of graft biopsy. Sixteen patients in the biomarker group and nineteen in the control group completed the study. The mean estimated glomerular filtration rate after KT did not differ between the groups. Graft biopsy was performed in two patients (12.5%) and nine (47.4%) in the biomarker and control groups, respectively, with the proportion being significantly lower in the biomarker group (p = 0.027). One patient (6.3%) in the biomarker group and two (10.5%) in the control group were diagnosed with AR, and the AR incidence did not differ between the groups. The tacrolimus trough level was significantly lower in the biomarker group than in the control group at 1 year after KT (p = 0.006). Integrated omics biomarker monitoring may help prevent unnecessary or high-complication-risk biopsy and enables tailored immunosuppression by predicting the risk of AR in KTRs.


  • Open Access

    Polyarteritis Nodosa Confined to the Kidneys in a Patient with Proteinuria and Mild Renal Impairment

    by Young Kyeong Seo, Taehee Kim, Yeong Hoon Kim, Yunmi Kim, Hyuk Huh, Byeong Woo Kim

  • Open Access

    Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea

    by Eunjung Cho, Jung Tak Park, Tae-Hyun Yoo, Soo Wan Kim, Cheol Whee Park, Seung Seok Han, Yeong Hoon Kim, Young Joo Kwon

    Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of α-galactosidase A (α-Gal A) enzyme, affecting multiple organs including kidney. In this study, we aimed to determine the prevalence of FD in patients with chronic kidney disease (CKD) including those on renal replacement therapy in Korea.Methods: This is a national, multicenter, observational study performed between August 24, 2017 and February 28, 2020. Patients with the presence of proteinuria or treated on dialysis were screened by measuring the α-Gal A enzyme activity using either dried blood spot or whole blood, and plasma globotriaosylsphingosine (lyso-GL3) concentration. A GLA gene analysis was performed in patients with low α-Gal A enzyme activity or increased plasma lyso-GL3 concentration.Results: Of 897 screened patients, 405 (45.2%) were male and 279 (31.1%) were on dialysis. The α-Gal A enzyme activity was measured in 891 patients (99.3%), and plasma lyso-GL3 concentration was measured in all patients. Ten patients were eligible for a GLA gene analysis: eight with low α-Gal A enzyme activity and two with increased plasma lyso-GL3 concentration. The GLA mutations were analyzed in nine patients and one patient was found with a pathogenic mutation. Therefore, one patient was identified with FD, giving a prevalence of 0.1% (1 of 897) in this CKD population.Conclusion: Although the prevalence of FD in the CKD population was low (0.1%), screening tests are crucial to detect potential diseases in patients with relatives who can benefit from early treatment.


  • Open Access

    Sex disparity in dialysis and kidney transplantation over 20 years in Korea

    by Miyeun Han, Jong Cheol Jeong, Yun Yung Cho, Curie Ahn, Yeong Hoon Kim

    Background: Sex disparity is prevalent in organ transplantations worldwide. This study aimed to understand sex disparities in dialysis and kidney transplantation in Korea over the last 20 years. Methods: Data for incident dialysis, waiting list registration, and donors and recipients were retrospectively collected between January 2000 and December 2020 from the Korean Society of Nephrology end-stage renal disease registry and the database of the Korean Network for Organ Sharing. Data regarding the proportion of females for dialysis, waiting list, and kidney transplantation donors or recipients were analyzed using linear regression analysis. Results: The average proportion of females on dialysis over the past 20 years was 40.5%. The proportion of females on dialysis was 42.8% in 2000, and decreased to 38.2% in 2020, showing a decreasing trend. The average proportion of women on the waiting list was 38.4%, which was lower than that for dialysis. The average proportion of female recipients in living donor kidney transplantation and female living donors were 40.1% and 53.2%, respectively. The overall proportion of female donors in living donor kidney transplantation showed an increasing trend. However, there was no change in the proportion of female recipients in living donor kidney transplantation. Conclusion: Sex disparities in organ transplantation exist, including an increasing trend of female donors in living donor kidney transplantation. Further studies are needed to identify the biological and socioeconomic factors involved to resolve these disparities.